Bioxytran (BIXT) Emerging Growth Conference 88 summary

Company overview and technology platforms

• Clinical stage biotech with three carbohydrate-based platform technologies: antivirals, oxygenation molecule for stroke, and cancer metastasis prevention.

• Lead antiviral drug achieved 100% viral reduction in seven days in clinical trials and targets COVID-19, influenza, and RSV.

• Oxygenation molecule designed for early stroke treatment, supported by an FDA-approved device for tissue oxygenation monitoring.

• Cancer metastasis platform aims to prevent tumor spread using carbohydrate drugs.

• All platforms target root causes of diseases, not just symptoms.

Clinical trial updates and future plans

• Dose escalation trial enrollment completed; top-line data readout expected before year-end.

• No significant safety issues observed in current or past trials.

• Phase three trial will be optimized for the Indian market and include all-comers with upper respiratory tract infections.

• Future trials will not exclude patients with underlying conditions to speed up recruitment.

Research and market potential

• In-depth 29-page research report available for institutional investors, highlighting broad drug potential for pandemics and common cold.

• Stroke drug targets a market larger than the $6–7 billion tPA market by providing an oxygen bridge during stroke onset.

• Each platform addresses multi-billion-dollar disease opportunities.